Affibody Announces Option Exercise by Biotest

Pressmeddelanden   •   Dec 04, 2018 07:15 CET

Solna, Sweden, December 4, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that its partner Biotest, a Germany-based biotherapeutic company, has exercised an option under the two companies’ ongoing collaboration.

Interim Report – January to September 2018

Pressmeddelanden   •   Nov 16, 2018 08:30 CET

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter 2018.

New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment

Pressmeddelanden   •   Sep 24, 2018 13:00 CEST

Solna, Sweden, September 24, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that a major Nordic study (“Affibody-3”) will begin using Affibody’s PET imaging agent ABY-025.

Interim Report – January to June 2018

Pressmeddelanden   •   Aug 23, 2018 08:15 CEST

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the second quarter 2018.

Affibody Presents at Anglonordic Life Science

Pressmeddelanden   •   Maj 21, 2018 09:00 CEST

Solna, Sweden, May 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Anglonordic Life Science conference, a UK and Nordic life science conference.

Interim Report – January to March 2018

Pressmeddelanden   •   Maj 18, 2018 09:00 CEST

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the first quarter 2018.

Affibody Presents at Bio€quity Europe

Pressmeddelanden   •   Maj 11, 2018 09:00 CEST

Solna, Sweden, May 11, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Bio€quity Europe, an investor and partnering event.

Kallelse till årsstämma

Pressmeddelanden   •   Maj 09, 2018 09:00 CEST

Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma onsdagen den 13 juni 2018 klockan 13.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.

Affibody Announces First Psoriasis Patients Dosed in a Phase II Clinical Trial of ABY-035

Pressmeddelanden   •   Mar 21, 2018 08:00 CET

Solna, Sweden, March 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced dosing of the first patients in a Phase II proof-of-concept study of ABY-035 in patients with moderate-to-severe psoriasis.

Affibody Announces First Dosing in a Phase I Trial of ABY-039 for Autoimmune Diseases

Pressmeddelanden   •   Mar 13, 2018 08:00 CET

Solna, Sweden, March 13, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced first dosing in a Phase I proof-of-principle study of ABY-039, a potential best-in-class therapy for the treatment of B-cell driven autoimmune diseases.

Bilder & Videor 1 bild

Kontaktpersoner 4 kontaktpersoner

Om Affibody

Developing Next Generation Biopharmaceuticals

Affibody is a clinical stage Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

The company operates a focused experimental medicine model and currently has four clinical or late stage preclinical proprietary programs. The first three are therapeutic programs that targets psoriasis, B-cell driven autoimmune diseases, and liver diseases respectively. The fourth program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum.

Adress

  • Affibody
  • Gunnar Asplunds Allé 24
  • SE-171 69 SOLNA